BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15497929)

  • 21. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
    Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K
    Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
    Rauvala M; Turpeenniemi-Hujanen T; Puistola U
    Anticancer Res; 2006; 26(6C):4779-84. PubMed ID: 17214341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
    Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
    J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
    Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
    Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production of matrix metalloproteinases and their inhibitors in osteoarthritic patients undergoing mud bath therapy.
    Bellometti S; Richelmi P; Tassoni T; Bertè F
    Int J Clin Pharmacol Res; 2005; 25(2):77-94. PubMed ID: 16060398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
    O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
    Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
    Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
    Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
    Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
    Hum Pathol; 2006 Oct; 37(10):1316-23. PubMed ID: 16949931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
    Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
    Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
    Rohini G; Murugeswari P; Prajna NV; Lalitha P; Muthukkaruppan V
    Cornea; 2007 Feb; 26(2):207-11. PubMed ID: 17251814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum matrix metalloproteinase and tissue inhibitor of metalloproteinase concentrations in infertile women achieved pregnancy following IVF-ET.
    Shibahara H; Suzuki T; Kikuchi K; Hirano Y; Suzuki M
    Am J Reprod Immunol; 2005 Oct; 54(4):186-92. PubMed ID: 16135009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
    Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers.
    Mwaura B; Mahendran B; Hynes N; Defreitas D; Avalos G; Adegbola T; Adham M; Connolly CE; Sultan S
    Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):306-10. PubMed ID: 16169261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.